Novartis earmarks $500M for new Brazilian vax plant; Hep E vaccine a success in clinical trial;
Vaccine Market
Novartis is planning to invest about a half billion dollars in a new vaccine plant in Brazil. Report
New Jersey has one of the lowest vaccination rates in the U.S., and health officials in the state say they've seen the trend building for years. Story
The World Health Organization has approved the use of Pfizer's Prevnar 13 pediatric vaccine. Estimates sales of the vaccine are projected to hit up to $6 billion by 2016. Report
Emergent BioSolutions named John Niederhuber, M.D. as a Class III Director for a two-year term that will expire at the 2012 annual meeting of stockholders. Emergent release
Ireland is welcoming the arrival of a new vaccine to guard against meningitis. Story
Vaccine Research
Chinese researchers are reporting the success of a new hepatitis E vaccine in a recent clinical trial. They said that even an incomplete dosing regimen appeared to work against the virus. Story
Merck has agreed to buy a dengue vaccine program from Hawaii Biotech for $3.1 million. Hawaii Biotech filed for bankruptcy at the end of last year. Report
Nabi announced the receipt of a patent for treating and preventing nicotine addiction with NicVAX and related nicotine conjugate vaccines. Nabi release
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities

SHARE
WITH: